Financial Advocates Investment Management Reduces Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS)

Financial Advocates Investment Management decreased its holdings in Gossamer Bio, Inc. (NASDAQ:GOSS) by 16.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 78,616 shares of the company’s stock after selling 14,934 shares during the quarter. Financial Advocates Investment Management’s holdings in Gossamer Bio were worth $71,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GOSS. The Manufacturers Life Insurance Company lifted its stake in Gossamer Bio by 67.4% in the second quarter. The Manufacturers Life Insurance Company now owns 310,213 shares of the company’s stock worth $279,000 after acquiring an additional 124,913 shares during the period. Sequoia Financial Advisors LLC raised its holdings in Gossamer Bio by 26.7% in the third quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock worth $117,000 after purchasing an additional 25,000 shares in the last quarter. US Bancorp DE bought a new position in Gossamer Bio in the third quarter worth $39,000. GSA Capital Partners LLP bought a new position in Gossamer Bio in the third quarter worth $67,000. Finally, Jacobs Levy Equity Management Inc. raised its holdings in Gossamer Bio by 30.7% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company’s stock worth $1,862,000 after purchasing an additional 442,895 shares in the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Price Performance

Shares of NASDAQ:GOSS opened at $1.17 on Tuesday. Gossamer Bio, Inc. has a 1-year low of $0.50 and a 1-year high of $1.60. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. The business has a fifty day moving average price of $0.91 and a 200-day moving average price of $0.90. The company has a market capitalization of $265.12 million, a PE ratio of -3.66 and a beta of 1.81.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Gossamer Bio in a report on Thursday, January 30th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $9.20.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.